• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miRNA-148a-3p 通过靶向 PD-L1 调节 DNA 错配修复缺陷型结直肠癌中的免疫抑制。

miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.

机构信息

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

出版信息

Mol Cancer Res. 2019 Jun;17(6):1403-1413. doi: 10.1158/1541-7786.MCR-18-0831. Epub 2019 Mar 14.

DOI:10.1158/1541-7786.MCR-18-0831
PMID:30872332
Abstract

Immunotherapy against the interaction between programmed cell death 1/programmed cell death ligand 1 (PD-L1) has emerged as a promising strategy for colorectal cancer with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). The study aimed to identify miRNAs that posttranscriptionally control PD-L1 expression on tumor cells and also regulate immune evasion. A comprehensive miRNA screening using The Cancer Genome Atlas (TCGA) dataset ( = 260) combined with eight different miRNA target prediction programs resulted in the identification of a tumor suppressive miRNA, miR-148a-3p, as a potential negative regulator of PD-L1 expression, particularly in dMMR/MSI-H colorectal cancer. Using multiple cohorts of colorectal cancer, including TCGA data, a microarray dataset ( = 148), and formalin-fixed, paraffin-embedded samples ( = 395), we found that the expression of miR-148a-3p was decreased in dMMR/MSI-H tumors, correlating inversely with PD-L1 levels. We demonstrate that miR-148a-3p directly binds to the 3'-untranslated region of PD-L1, thereby reducing whole-cell and cell surface PD-L1 levels in HCT116 and SW837 cell lines. Overexpression of miR-148a-3p repressed IFNγ-induced PD-L1 expression on tumor cells and consequently diminished T-cell apoptosis in a coculture model of IL2-activated T cells and IFNγ-treated tumor cells. In conclusion, our data support a regulatory mechanism of PD-L1 expression on tumor cells and immune suppression via miR-148a-3p downregulation in colorectal cancer. IMPLICATIONS: This study provides novel evidence that miR-148a-3p negatively regulates tumor cell PD-L1 expression and decreased levels of miR-148a-3p contributes to the immunosuppressive tumor microenvironment.

摘要

免疫疗法针对程序性细胞死亡 1/程序性细胞死亡配体 1(PD-L1)的相互作用,已成为具有错配修复缺陷(dMMR)或微卫星不稳定高(MSI-H)的结直肠癌的一种有前途的策略。本研究旨在鉴定在肿瘤细胞上转录后控制 PD-L1 表达并调节免疫逃逸的 miRNA。使用癌症基因组图谱(TCGA)数据集(= 260)与八种不同的 miRNA 靶标预测程序相结合的全面 miRNA 筛选,鉴定出一种肿瘤抑制性 miRNA,miR-148a-3p,作为 PD-L1 表达的潜在负调节剂,特别是在 dMMR/MSI-H 结直肠癌中。使用包括 TCGA 数据、微阵列数据集(= 148)和福尔马林固定、石蜡包埋样本(= 395)在内的多个结直肠癌队列,我们发现 miR-148a-3p 在 dMMR/MSI-H 肿瘤中表达降低,与 PD-L1 水平呈负相关。我们证明 miR-148a-3p 直接结合 PD-L1 的 3'-非翻译区,从而降低 HCT116 和 SW837 细胞系中的全细胞和细胞表面 PD-L1 水平。miR-148a-3p 的过表达抑制了肿瘤细胞中 IFNγ 诱导的 PD-L1 表达,并在 IL2 激活的 T 细胞和 IFNγ 处理的肿瘤细胞共培养模型中减少了 T 细胞凋亡。总之,我们的数据支持 PD-L1 表达的调节机制,以及 miR-148a-3p 通过下调在结直肠癌中抑制肿瘤细胞和免疫抑制的机制。

意义

本研究提供了新的证据,表明 miR-148a-3p 负调控肿瘤细胞 PD-L1 表达,并且 miR-148a-3p 水平降低有助于免疫抑制的肿瘤微环境。

相似文献

1
miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.miRNA-148a-3p 通过靶向 PD-L1 调节 DNA 错配修复缺陷型结直肠癌中的免疫抑制。
Mol Cancer Res. 2019 Jun;17(6):1403-1413. doi: 10.1158/1541-7786.MCR-18-0831. Epub 2019 Mar 14.
2
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.PD-L1 抑制 microRNA 治疗结直肠癌潜力的范围综述:迈向单细胞测序指导的生物相容性递送。
Biomed Pharmacother. 2021 Nov;143:112213. doi: 10.1016/j.biopha.2021.112213. Epub 2021 Sep 22.
3
MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.MicroRNA-124-3p 通过调控 STAT3 信号通路抑制 PD-L1 表达并抑制结直肠癌细胞的肿瘤生成。
J Cell Physiol. 2021 Oct;236(10):7071-7087. doi: 10.1002/jcp.30378. Epub 2021 Apr 5.
4
[Regulation of PD-L1 by MicroRNA in Mismatch Repair Deficient-Colorectal Cancer].[错配修复缺陷型结直肠癌中微小RNA对程序性死亡配体1的调控]
Gan To Kagaku Ryoho. 2017 Oct;44(10):889-891.
5
Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.错配修复缺陷型结直肠癌:尽管肿瘤细胞中程序性细胞死亡配体 1 的表达无显著意义,但仍是一种免疫原性和免疫细胞丰富的肿瘤模型。
Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.
6
High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.在结直肠癌中,无论错配修复状态如何,高细胞毒性 T 淋巴细胞密度与肿瘤 PD-L1 表达相关。
Acta Oncol. 2021 Sep;60(9):1210-1217. doi: 10.1080/0284186X.2021.1933585. Epub 2021 Jun 5.
7
Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.内质网应激诱导的外泌体 miR-27a-3p 通过调节巨噬细胞中 PD-L1 的表达促进乳腺癌的免疫逃逸。
J Cell Mol Med. 2020 Sep;24(17):9560-9573. doi: 10.1111/jcmm.15367. Epub 2020 Jul 16.
8
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.免疫治疗治疗的微卫星不稳定/错配修复缺陷型结直肠癌队列的综合生物标志物分析。
Int J Mol Sci. 2022 Dec 21;24(1):118. doi: 10.3390/ijms24010118.
9
Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.对干扰素 γ 暴露的高反应性作为抗 PD-1 治疗在微卫星不稳定结直肠癌中的反应机制。
Cancer Immunol Immunother. 2019 Feb;68(2):257-268. doi: 10.1007/s00262-018-2270-5. Epub 2018 Nov 7.
10
miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.miR-105-5p 调控胃癌中 PD-L1 的表达和肿瘤免疫原性。
Cancer Lett. 2021 Oct 10;518:115-126. doi: 10.1016/j.canlet.2021.05.037. Epub 2021 Jun 23.

引用本文的文献

1
GIN-CRC-Pareto: A graph-based Pareto-optimal multi-task learning framework to identify miRNA-target interactions in colorectal cancer.GIN-CRC-Pareto:一种基于图的帕累托最优多任务学习框架,用于识别结直肠癌中的miRNA-靶标相互作用。
bioRxiv. 2025 Aug 12:2025.08.10.669528. doi: 10.1101/2025.08.10.669528.
2
GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression.GALNT7将错配修复缺陷/微卫星高度不稳定的结直肠癌分层为与预后和程序性死亡配体1表达相关的不同分子亚群。
Cancer Res Commun. 2025 Sep 1;5(9):1530-1540. doi: 10.1158/2767-9764.CRC-25-0270.
3
PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities.
PD-L1在恶性肿瘤中的重要性:对PD-L1在恶性肿瘤中作用的全面见解,从分子机制到治疗机遇
Clin Exp Med. 2025 Apr 3;25(1):106. doi: 10.1007/s10238-025-01641-y.
4
Emerging role of small RNAs in inflammatory bowel disease and associated colorectal cancer (Review).小RNA在炎症性肠病及相关结直肠癌中的新作用(综述)
Int J Mol Med. 2025 Feb;55(2). doi: 10.3892/ijmm.2024.5474. Epub 2024 Dec 20.
5
Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy.肿瘤中的免疫调节 microRNAs,其在诊断和治疗中的临床相关性。
J Immunother Cancer. 2024 Aug 29;12(8):e009774. doi: 10.1136/jitc-2024-009774.
6
Synthesis and Regulation of miRNA, Its Role in Oncogenesis, and Its Association with Colorectal Cancer Progression, Diagnosis, and Prognosis.微小RNA的合成与调控、其在肿瘤发生中的作用及其与结直肠癌进展、诊断和预后的关联
Diagnostics (Basel). 2024 Jul 7;14(13):1450. doi: 10.3390/diagnostics14131450.
7
A study of microRNAs as new prognostic biomarkers in anal cancer patients.一项关于 microRNAs 作为肛门癌患者新的预后生物标志物的研究。
Acta Oncol. 2024 Jun 20;63:456-465. doi: 10.2340/1651-226X.2024.27976.
8
Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer.转移性结直肠癌的分子亚型、microRNAs 和免疫治疗反应。
Medicina (Kaunas). 2024 Feb 26;60(3):397. doi: 10.3390/medicina60030397.
9
Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis.确定经典型霍奇金淋巴瘤发病机制中功能相关的微小RNA
Cancers (Basel). 2024 Mar 12;16(6):1126. doi: 10.3390/cancers16061126.
10
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.微小RNA作为癌症免疫治疗中免疫检查点的调节因子:靶向程序性死亡受体1/程序性死亡受体配体1和细胞毒性T淋巴细胞相关蛋白4通路
Cancer Cell Int. 2024 Mar 10;24(1):102. doi: 10.1186/s12935-024-03293-6.